ArticleCell reports. Medicine2023

NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.

Laura Hurtado-Navarro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.